- Home
- BCAB vs BNR Comparison
BCAB vs BNR Comparison
Compare BCAB & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- BNR
- Stock Information
- Founded
- BCAB 2007
- BNR 2014
- Country
- BCAB United States
- BNR China
- Employees
- BCAB N/A
- BNR N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- BNR Medical Specialities
- Sector
- BCAB Health Care
- BNR Health Care
- Exchange
- BCAB Nasdaq
- BNR Nasdaq
- Market Cap
- BCAB 22.3M
- BNR 29.1M
- IPO Year
- BCAB 2020
- BNR 2020
- Fundamental
- Price
- BCAB $0.41
- BNR $3.10
- Analyst Decision
- BCAB Buy
- BNR
- Analyst Count
- BCAB 2
- BNR 0
- Target Price
- BCAB $1.00
- BNR N/A
- AVG Volume (30 Days)
- BCAB 421.1K
- BNR 68.0K
- Earning Date
- BCAB 05-06-2025
- BNR 06-10-2025
- Dividend Yield
- BCAB N/A
- BNR N/A
- EPS Growth
- BCAB N/A
- BNR N/A
- EPS
- BCAB N/A
- BNR N/A
- Revenue
- BCAB $11,000,000.00
- BNR $70,669,261.00
- Revenue This Year
- BCAB N/A
- BNR $136.32
- Revenue Next Year
- BCAB N/A
- BNR N/A
- P/E Ratio
- BCAB N/A
- BNR N/A
- Revenue Growth
- BCAB N/A
- BNR N/A
- 52 Week Low
- BCAB $0.24
- BNR $2.18
- 52 Week High
- BCAB $2.53
- BNR $7.90
- Technical
- Relative Strength Index (RSI)
- BCAB 50.31
- BNR 51.73
- Support Level
- BCAB $0.37
- BNR $2.99
- Resistance Level
- BCAB $0.42
- BNR $3.45
- Average True Range (ATR)
- BCAB 0.04
- BNR 0.34
- MACD
- BCAB -0.01
- BNR 0.10
- Stochastic Oscillator
- BCAB 35.88
- BNR 70.59
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.